Clinical-stage biotechnology company developing cis-targeted immunotherapies that selectively activate specific immune cell types
Clinical-stage biotechnology company developing cis-targeted immunotherapies that selectively activate specific immune cell types. Its lead program, etakafusp alfa, is an IL-2 therapy targeted to CD8+ effector T cells for solid tumors; the platform is also being applied to cancer, autoimmune, and infectious diseases.